記住我
Jering KS, Claggett B, Pfeffer MA, et al. Prospective ARNI vs. ACE inhibitor trial to DetermIne Superiority in reducing heart failure Events after Myocardial Infarction (PARADISE-MI): design and baseline characteristics. Eur J He art Fail 2021; 23: 1040–1048.
[17]Angiotensin-neprilysin inhibition in acute decompensated heart failure. N Engl J Med 2019; 380: 1090.
[18] Peri-Okonny PA, Mi X, Khariton Y, et al. Target doses of heart failure medical therapy and blood pressure: insights from the CHAMP-HF registry. JACC Heart Fail 2019; 7: 350−358. doi: 10.1016/j.jchf.2018.11.011 [19] Veenis JF, Brunner-La Rocca HP, Linssen GCM, et al. Treatment differences in chronic heart failure patients with reduced ejection fraction according to blood pressure. Circ Heart Fail 2020; 13: e006667. doi: 10.1161/CIRCHEARTFAILURE.119.006667 [20] Pandey AC, Jer D, Kuo RS, et al. Novel doses of sacubitril/valsartan in patients unable to tolerate traditional therapy: effects on N-terminal pro B-type natriuretic peptide levels. Clin Cardiol 2021; 44: 85−90. doi: 10.1002/clc.23509 [21] Kim H, Oh J, Lee S, et al. Clinical evidence of initiating a very low dose of sacubitril/valsartan: a prospective observational analysis. Sci Rep 2021; 11: 16335. doi: 10.1038/s41598-021-95787-w [22] Hu J, Wu Y, Zhou X, et al. Beneficial effects of sacubitril/valsartan at low doses in an Asian real-world heart failure population. J Cardiovasc Pharmacol 2020; 76: 445−451. doi: 10.1097/FJC.0000000000000873 [23] Kido K, Bianco C, Caccamo M, et al. Evaluating sacubitril/valsartan dose dependence on clinical outcomes in patients with heart failure with reduced ejection fraction. Ann Pharmacother 2021; 55: 1069−1075. doi: 10.1177/1060028020983522 [24] Corrado E, Dattilo G, Coppola G, et al. Low- vs high-dose ARNI effects on clinical status, exercise performance and cardiac function in real-life HFrEF patients. Eur J Clin Ph armacol 2022; 78: 19−25. doi: 10.1007/s00228-021-03210-0 [25] Chang HY, Feng AN, Fong MC, et al. Sacubitril/valsartan in heart failure with reduced ejection fraction patients: real world experience on advanced chronic kidney disease, hypotension, and dose escalation. J Cardiol 2019; 74: 372−380. doi: 10.1016/j.jjcc.2019.03.010 [26] Rouleau JL, Roecker EB, Tendera M, et al. Influence of pretreatment systolic blood pressure on the effect of carvedilol in patients with severe chronic heart failure: the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) study. J Am Coll Cardiol 2004; 43: 1423−1429. doi: 10.1016/j.jacc.2003.11.037 [27] Vardeny O, Claggett B, Kachadourian J, et al. Incidence, predictors, and outcomes associated with hypotensive episodes among heart failure patients receiving sacubitril/valsartan or enalapril: the PARADIGM-HF (Prospective Comparison of Angiotensin Receptor Neprilysin Inhibitor With Angiotensin-Converting Enzyme Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure) trial. Circ Heart Fail 2018; 11: e004745. doi: 10.1161/CIRCHEARTFAILURE.117.004745 [28] Velazquez EJ, Morrow DA, DeVore AD, et al. Angiotensin-neprilysin inhibition in acute decompensated heart failure. N Engl J Med 2019; 380: 539−548. doi: 10.1056/NEJMoa1812851 [29] Wachter R, Senni M, Belohlavek J, et al. Initiation of sacubitril/valsartan in haemodynamically stabilised heart failure patients in hospital or early after discharge: primary results of the randomised TRANSITION study. Eur J He art Fail 2019; 21: 998−1007. doi: 10.1002/ejhf.1498 [30] Rosano GMC, Moura B, Metra M, et al. Patient profiling in heart failure for tailoring medical therapy. A consensus document of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2021; 23: 872−881. doi: 10.1002/ejhf.2206 [31] Ameri P, Bertero E, Maack C, et al. Medical treatment of heart failure with reduced ejection fraction: the dawn of a new era of personalized treatment?. Eur Heart J Cardiov asc Pharmacother 2021; 7: 539−546. doi: 10.1093/ehjcvp/pvab033
留言 (0)